{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:13:57Z","timestamp":1775013237773,"version":"3.50.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","award":["2122-HQ-000231"],"award-info":[{"award-number":["2122-HQ-000231"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To inform updated recommendations by the Canadian Task Force on Preventive Health Care on screening for prostate cancer in adults aged 18 years and older in primary care. This protocol outlines the planned scope and methods for a series of systematic reviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Updates of two systematic reviews and a de novo review will be conducted to synthesize the evidence on the benefits and harms of screening for prostate cancer with a prostate-specific antigen (PSA) and\/or digital rectal examination (DRE) (with or without additional information) and patient values and preferences. Outcomes for the benefits of screening include reduced prostate cancer mortality, all-cause mortality, and incidence of metastatic prostate cancer. Outcomes for the harms of screening include false-positive screening tests, overdiagnosis, complications due to biopsy, and complications of treatment including incontinence (urinary or bowel), and erectile dysfunction. The quality of life or functioning (overall and disease-specific) and psychological effects outcomes are considered as a possible benefit or harm. Outcomes for the values and preferences review include quantitative or qualitative information regarding the choice to screen or intention to undergo screening. For the reviews on benefits or harms, we will search for randomized controlled trials, quasi-randomized, and controlled studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. For the review on values and preferences, we will search for experimental or observational studies in MEDLINE, Embase, and PsycInfo. For all reviews, we will also search websites of relevant organizations, gray literature, and reference lists of included studies. Title and abstract screening, full-text review, data extraction, and risk of bias assessments will be completed independently by pairs of reviewers with any disagreements resolved by consensus or by consulting with a third reviewer. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach will be used to assess the certainty of the evidence for each outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The series of systematic reviews will be used by the Canadian Task Force on Preventive Health Care to update their 2014 guideline on screening for prostate cancer in adults aged 18 years and older.<\/jats:p>\n                <jats:p>Systematic review registration<\/jats:p>\n                <jats:p>This review has been registered with PROSPERO (CRD42022314407) and is available on the Open Science Framework (osf.io\/dm32k).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-022-02099-9","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T18:04:31Z","timestamp":1666807471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-2094","authenticated-orcid":false,"given":"Alexandria","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-2202","authenticated-orcid":false,"given":"Andrew","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Grad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allana","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Limburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abou-Setta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Klarenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navindra","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guyl\u00e8ne","family":"Th\u00e9riault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett D.","family":"Thombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith J.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Rolland-Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-4206","authenticated-orcid":false,"given":"David","family":"Moher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"2099_CR1","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1503\/cmaj.140703","volume":"186","author":"N Bell","year":"2014","unstructured":"Bell N, Gorber SC, Shane A, Joffres M, Singh H, Dickinson J, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186:1225\u201334.","journal-title":"CMAJ"},{"key":"2099_CR2","unstructured":"What is prostate cancer? Canadian Cancer Society. Available from:\u00a0https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/prostate\/prostate-cancer\/?region=on. Accessed 30 Mar 2021."},{"key":"2099_CR3","unstructured":"TNM staging for prostate cancer. Cancer Research UK. 2019. Available from:\u00a0 \u00a0https:\/\/www.cancerresearchuk.org\/about-cancer\/prostate-cancer\/stages\/tnm-staging. Accessed 30 Mar 2021."},{"key":"2099_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology Prostate Cancer. NCCN Guidelines. 2017. Available from:\u00a0https:\/\/www.nccn.org\/patientresources\/patient-resources. Accessed 17 Feb 2021."},{"key":"2099_CR5","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto: Canadian Cancer Society; 2019. Available from: Cancer.ca\/Canadian-Cancer-Statistics-2019-EN. Accessed 27 Feb 2020."},{"key":"2099_CR6","first-page":"12","volume":"30","author":"AG LeBlanc","year":"2019","unstructured":"LeBlanc AG, Demers A, Shaw A. Recent trends in prostate cancer in Canada. Health Rep. 2019;30:12\u20137.","journal-title":"Health Rep"},{"key":"2099_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352.","journal-title":"Am J Surg Pathol"},{"key":"2099_CR8","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1503\/cmaj.191292","volume":"192","author":"DR Brenner","year":"2020","unstructured":"Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192:E199\u2013205.","journal-title":"CMAJ"},{"key":"2099_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.juro.2017.10.044","volume":"199","author":"F Pishgar","year":"2018","unstructured":"Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E. Global, regional and national burden of prostate cancer, 1990 to 2015: results from the global burden of disease study 2015. j Urol. 2018;199:1224\u201332.","journal-title":"j Urol"},{"key":"2099_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJ Bell","year":"2015","unstructured":"Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137:1749\u201357.","journal-title":"Int J Cancer"},{"key":"2099_CR11","unstructured":"Prostate Cancer Statistics. Canadian Cancer Society Prostate cancer. Available from: https:\/\/www.cancer.ca:443\/en\/cancer-information\/cancer-type\/prostate\/statistics\/?region=on. Accessed 4 Aug 2021."},{"key":"2099_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7326\/M16-2586","volume":"167","author":"A Tsodikov","year":"2017","unstructured":"Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the Effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449\u201355.","journal-title":"Ann Intern Med"},{"key":"2099_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2020.11.022","volume":"149","author":"K Schmanke","year":"2021","unstructured":"Schmanke K, Okut H, Ablah E. Trends for stage and grade group of prostate cancer in the US (2010-2016). Urology. 2021;149:110\u20136.","journal-title":"Urology"},{"key":"2099_CR14","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.urology.2009.03.001","volume":"73","author":"ED Crawford","year":"2009","unstructured":"Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009;73:S4\u2013S10.","journal-title":"Urology"},{"key":"2099_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63\u201389.","journal-title":"World J Oncol"},{"key":"2099_CR16","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/cncr.20408","volume":"101","author":"DG Bostwick","year":"2004","unstructured":"Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371\u2013490.","journal-title":"Cancer"},{"key":"2099_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/aja.2011.150","volume":"14","author":"E Castro","year":"2012","unstructured":"Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409\u201314.","journal-title":"Asian J Androl"},{"key":"2099_CR18","first-page":"S92","volume":"3","author":"Y Fradet","year":"2009","unstructured":"Fradet Y, Klotz L, Trachtenberg J, Zlotta A. The burden of prostate cancer in Canada. Can Urol Assoc J J Assoc Urol Can. 2009;3:S92\u2013S100.","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"key":"2099_CR19","first-page":"3866","volume":"15","author":"GP Haas","year":"2008","unstructured":"Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866\u201371.","journal-title":"Can J Urol"},{"key":"2099_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer\u2013specific and other-cause mortality. JAMA Oncol. 2019;5:975.","journal-title":"JAMA Oncol"},{"key":"2099_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2105\/AJPH.2008.150508","volume":"100","author":"M Huncharek","year":"2010","unstructured":"Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693\u2013701.","journal-title":"Am J Public Health"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euf.2014.10.002","volume":"1","author":"C De Nunzio","year":"2015","unstructured":"De Nunzio C, Andriole GL, Thompson IM Jr, Freedland SJ. Smoking and prostate cancer: a systematic review. Eur Urol Focus. 2015;1:28\u201338.","journal-title":"Eur Urol Focus"},{"key":"2099_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.7326\/0003-4819-118-10-199305150-00007","volume":"118","author":"KJ Pienta","year":"1993","unstructured":"Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793\u2013803.","journal-title":"Ann Intern Med"},{"key":"2099_CR24","unstructured":"Canadian Population Attributable Risk of Cancer (ComPARe) study cancer types. Comp. Study Prev. Cancers Can. https:\/\/data.prevent.cancer.ca\/current\/cancer-types. Accessed 21 May 2021"},{"key":"2099_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.15430\/JCP.2019.24.2.91","volume":"24","author":"S Krstev","year":"2019","unstructured":"Krstev S, Knutsson A. Occupational risk factors for prostate cancer: a meta-analysis. J Cancer Prev. 2019;24:91\u2013111.","journal-title":"J Cancer Prev"},{"key":"2099_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/aje\/kwq493","volume":"173","author":"JM Schenk","year":"2011","unstructured":"Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173:1419\u201328.","journal-title":"Am J Epidemiol"},{"key":"2099_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.eururo.2011.06.016","volume":"60","author":"DD \u00d8rsted","year":"2011","unstructured":"\u00d8rsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men. Eur Urol. 2011;60:691\u20138.","journal-title":"Eur Urol"},{"key":"2099_CR28","doi-asserted-by":"publisher","first-page":"k1202","DOI":"10.1136\/bmj.k1202","volume":"361","author":"J\u00d8 J\u00e1kupsstovu","year":"2018","unstructured":"J\u00e1kupsstovu J\u00d8, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ. 2018;361:k1202.","journal-title":"BMJ"},{"key":"2099_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7150\/jca.37235","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wang Y, Qin Z, Gao X, Xing Q, Li R, et al. Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: a systematic review and meta-analysis. J Cancer. 2020;11:177\u201389.","journal-title":"J Cancer"},{"key":"2099_CR30","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/ijc.23713","volume":"123","author":"RM Martin","year":"2008","unstructured":"Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer. 2008;123:1924\u20138.","journal-title":"Int J Cancer"},{"key":"2099_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/tre.95","volume":"14","author":"J Melia","year":"2009","unstructured":"Melia J, Moss S. PSA testing in the UK. Trends Urol Gynaecol Sex Health. 2009;14:9\u201313.","journal-title":"Trends Urol Gynaecol Sex Health"},{"key":"2099_CR32","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.9778\/cmajo.20140079","volume":"4","author":"J Dickinson","year":"2016","unstructured":"Dickinson J, Shane A, Tonelli M, Gorber SC, Joffres M, Singh H, et al. Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. CMAJ Open. 2016;4:E73\u20139.","journal-title":"CMAJ Open"},{"key":"2099_CR33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","volume":"324","author":"WJ Catalona","year":"1991","unstructured":"Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156\u201361.","journal-title":"N Engl J Med"},{"key":"2099_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3322\/canjclin.43.1.42","volume":"43","author":"C Mettlin","year":"1993","unstructured":"Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42\u20136.","journal-title":"CA Cancer J Clin"},{"key":"2099_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3747\/co.v16i3.459","volume":"16","author":"RJ Ablin","year":"2009","unstructured":"Ablin RJ, Haythorn MR. Screening for prostate cancer: controversy? What controversy? Curr Oncol. 2009;16:1\u20132.","journal-title":"Curr Oncol"},{"key":"2099_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.2014.2085","volume":"311","author":"JH Hayes","year":"2014","unstructured":"Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143\u20139.","journal-title":"JAMA"},{"key":"2099_CR37","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen\u2013based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319:1914\u201331.","journal-title":"JAMA"},{"key":"2099_CR38","unstructured":"Prostate-specific antigen (PSA) test. Canadian Cancer Society. Available from: https:\/\/www.cancer.ca:443\/en\/cancer-information\/diagnosis-and-treatment\/tests-and-procedures\/prostate-specific-antigen-psa\/?region=on. Accessed 20 May 2020."},{"key":"2099_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5489\/cuaj.4888","volume":"11","author":"RA Rendon","year":"2017","unstructured":"Rendon RA, Mason RJ, Marzouk K, Finelli A, Saad F, So A, et al. Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Can Urol Assoc J. 2017;11:298\u2013309.","journal-title":"Can Urol Assoc J"},{"key":"2099_CR40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901\u201313.","journal-title":"JAMA"},{"key":"2099_CR41","unstructured":"Young S, Bansal P, Vella E, Finelli A, Levitt C, Loblaw A, et al. Referral of suspected prostate cancer by family physicians and other primary care providers. Cancer Care Ont. 2016; Available from: https:\/\/www.cancercareontario.ca\/en\/content\/referral-suspected-prostate-cancer-family-physicians-and-other-primary-care-providers. Accessed 28 May 2021."},{"key":"2099_CR42","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","volume":"57","author":"FH Jansen","year":"2010","unstructured":"Jansen FH, van Schaik RHN, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) Isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010;57:921\u20137.","journal-title":"Eur Urol"},{"key":"2099_CR43","doi-asserted-by":"crossref","unstructured":"Lavall\u00e9e LT, Binette A, Witiuk K, Cnossen S, Mallick R, Fergusson DA, et al. Reducing the harm of prostate cancer screening: repeated prostate-specific antigen testing. Mayo Clin Proc. Elsevier. 2016;91:17\u201322.","DOI":"10.1016\/j.mayocp.2015.07.030"},{"key":"2099_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"L Naji","year":"2018","unstructured":"Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med. 2018;16:149\u201354.","journal-title":"Ann Fam Med"},{"key":"2099_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","volume":"199","author":"JA Halpern","year":"2018","unstructured":"Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, et al. Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer. J Urol. 2018;199:947\u201353.","journal-title":"J Urol"},{"key":"2099_CR46","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1155\/2012\/681357","volume":"26","author":"A Nensi","year":"2012","unstructured":"Nensi A, Chande N. A survey of digital rectal examination training in canadian medical schools. Can J Gastroenterol. 2012;26:441\u20134.","journal-title":"Can J Gastroenterol"},{"key":"2099_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ucl.2015.08.002","volume":"43","author":"MS Leapman","year":"2016","unstructured":"Leapman MS, Carroll PR. New genetic markers for prostate cancer. Urol Clin North Am. 2016;43:7\u201315.","journal-title":"Urol Clin North Am"},{"key":"2099_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MOU.0000000000000316","volume":"26","author":"S Loeb","year":"2016","unstructured":"Loeb S, Lilja H, Vickers A. Beyond PSA: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol. 2016;26:459.","journal-title":"Curr Opin Urol"},{"key":"2099_CR49","doi-asserted-by":"crossref","unstructured":"Zappala SM, Dong Y, Linder V, Reeve M, Sjoberg DD, Mathur V, Roberts R, Okrongly D, Newmark J, Sant G, Steiner M. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. Int J Clin Pract. 2017;71(6):e12943.","DOI":"10.1111\/ijcp.12943"},{"key":"2099_CR50","first-page":"231","volume":"17","author":"B Konety","year":"2015","unstructured":"Konety B, Zappala SM, Parekh DJ, Osterhout D, Schock J, Chudler RM, et al. The 4Kscore\u00ae test reduces prostate biopsy rates in community and academic urology practices. Rev Urol. 2015;17:231\u201340.","journal-title":"Rev Urol"},{"key":"2099_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41391-017-0008-7","volume":"21","author":"J White","year":"2018","unstructured":"White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018;21:78\u201384.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2099_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-015-0127-8","volume":"34","author":"R Merola","year":"2015","unstructured":"Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res CR. 2015;34:15.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"2099_CR53","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaoncol.2017.0177","volume":"3","author":"MG Sanda","year":"2017","unstructured":"Sanda MG, Feng Z, Howard DH, et al. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol. 2017;3:1085\u201393.","journal-title":"JAMA Oncol"},{"key":"2099_CR54","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","volume":"73","author":"V Cucchiara","year":"2018","unstructured":"Cucchiara V, Cooperberg MR, Dall\u2019Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73:572\u201382.","journal-title":"Eur Urol"},{"key":"2099_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/JU.0000000000000475","volume":"203","author":"X Lei","year":"2020","unstructured":"Lei X, Xueying M, Alistair G, et al. Noninvasive detection of clinically significant prostate cancer using circulating tumor cells. J Urol. 2020;203:73\u201382.","journal-title":"J Urol"},{"key":"2099_CR56","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000001430","volume":"205","author":"JJ Tosoian","year":"2021","unstructured":"Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. J Urol. 2021;205:732\u20139.","journal-title":"J Urol"},{"key":"2099_CR57","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1007\/s13277-015-4398-7","volume":"37","author":"S Li","year":"2016","unstructured":"Li S, Wu Z, Chen Y, et al. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37:5365\u201374.","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"2099_CR58","doi-asserted-by":"publisher","unstructured":"Flores-Fraile M-C, Padilla-Fern\u00e1ndez BY, Valverde-Mart\u00ednez S, Marquez-Sanchez M, Garc\u00eda-Cenador M-B, Lorenzo-G\u00f3mez M-F, et al. The association between prostate-specific antigen velocity (PSAV), value and acceleration, and of the free PSA\/total PSA index or ratio, with prostate conditions. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113400.","DOI":"10.3390\/jcm9113400"},{"key":"2099_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/bjc.2017.429","volume":"118","author":"C Mikropoulos","year":"2018","unstructured":"Mikropoulos C, Selkirk CGH, Saya S, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018;118:266\u201376.","journal-title":"Br J Cancer"},{"key":"2099_CR60","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.euf.2016.10.009","volume":"4","author":"M Eklund","year":"2018","unstructured":"Eklund M, Nordstr\u00f6m T, Aly M, et al. The Stockholm-3 (STHLM3) Model can improve prostate cancer diagnostics in men aged 50-69 yr compared with current prostate cancer testing. Eur Urol Focus. 2018;4:707\u201310.","journal-title":"Eur Urol Focus"},{"key":"2099_CR61","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667\u201376.","journal-title":"Lancet Oncol"},{"key":"2099_CR62","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","volume":"10","author":"I Yusim","year":"2020","unstructured":"Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10:20015.","journal-title":"Sci Rep"},{"key":"2099_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","volume":"21","author":"T Nordstr\u00f6m","year":"2018","unstructured":"Nordstr\u00f6m T, Akre O, Aly M, Gr\u00f6nberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:57\u201363.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2099_CR64","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2010.32.6371","volume":"29","author":"RK Nam","year":"2011","unstructured":"Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29:2959\u201364.","journal-title":"J Clin Oncol"},{"key":"2099_CR65","unstructured":"PCPT Risk Calculator. In: Prostate Prev. Trial Risk Calc. Version 20. http:\/\/www.riskcalc.org\/PCPTRC\/. Accessed 31 Mar 2021"},{"key":"2099_CR66","unstructured":"PBCG. PBCG Risk Calc. http:\/\/riskcalc.org:3838\/PBCG\/. Accessed 31 Mar 2021"},{"key":"2099_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74:197\u2013203.","journal-title":"Eur Urol"},{"key":"2099_CR68","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/bco2.58","volume":"2","author":"G Wei","year":"2021","unstructured":"Wei G, Kelly BD, Timm B, Perera M, Lundon DJ, Jack G, et al. Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy. BJUI Compass. 2021;2:194\u2013201.","journal-title":"BJUI Compass"},{"key":"2099_CR69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43\u201351.","journal-title":"Eur Urol"},{"key":"2099_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jnci\/djr500","volume":"104","author":"GL Andriole","year":"2012","unstructured":"Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"2099_CR71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3399\/bjgp18X699689","volume":"68","author":"J Just","year":"2018","unstructured":"Just J, Osgun F, Knight C. Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise? Br J Gen Pract. 2018;68:541\u20132.","journal-title":"Br J Gen Pract"},{"key":"2099_CR72","doi-asserted-by":"crossref","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.","DOI":"10.1136\/bmj.k3519"},{"key":"2099_CR73","doi-asserted-by":"publisher","unstructured":"Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database of Systematic Reviews. 2013;(1):CD004720. https:\/\/doi.org\/10.1002\/14651858.CD004720.pub3. Accessed 30 Mar 2021.","DOI":"10.1002\/14651858.CD004720.pub3"},{"key":"2099_CR74","doi-asserted-by":"crossref","unstructured":"Paschen U, Sturtz S, Fleer D, Lampert U, Skoetz N, Dahm P. Assessment of Prostate-Specific Antigen Screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care. BJU Int. 2022;129(3):280-9.","DOI":"10.1111\/bju.15444"},{"key":"2099_CR75","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046\u201355.","journal-title":"Eur Urol"},{"key":"2099_CR76","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/JU.0000000000001578","volume":"205","author":"TJ Wilt","year":"2021","unstructured":"Wilt TJ, Ullman KE, Linskens EJ, MacDonald R, Brasure M, Ester E, et al. Therapies for clinically localized prostate cancer: a comparative effectiveness review. J Urol. 2021;205:967\u201376.","journal-title":"J Urol"},{"key":"2099_CR77","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876\u201392.","journal-title":"Eur Urol"},{"key":"2099_CR78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1015290429403","volume":"33","author":"SR Gambert","year":"2001","unstructured":"Gambert SR. Screening for prostate cancer. Int Urol Nephrol. 2001;33:249\u201357.","journal-title":"Int Urol Nephrol"},{"key":"2099_CR79","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/caac.20066","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf AM, Wender RC, Etzioni RB, Thompson IM, D\u2019Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70\u201398.","journal-title":"CA Cancer J Clin"},{"key":"2099_CR80","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdu525","volume":"26","author":"KS Louie","year":"2015","unstructured":"Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26:848\u201364.","journal-title":"Ann Oncol"},{"key":"2099_CR81","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1186\/s12885-019-6434-2","volume":"19","author":"L Zhen","year":"2019","unstructured":"Zhen L, Liu X, Yegang C, et al. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:1244.","journal-title":"BMC Cancer"},{"key":"2099_CR82","doi-asserted-by":"publisher","first-page":"718","DOI":"10.7326\/M14-2326","volume":"162","author":"TJ Wilt","year":"2015","unstructured":"Wilt TJ, Harris RP, Qaseem A, High Value Care Task Force of the American College of Physicians. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:718\u201325.","journal-title":"Ann Intern Med"},{"key":"2099_CR83","doi-asserted-by":"crossref","unstructured":"Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581.","DOI":"10.1136\/bmj.k3581"},{"key":"2099_CR84","unstructured":"Clinical Preventive Service Recommendation: Prostate Cancer. American Academy of Family Physicians (AAFP). Available from:\u00a0https:\/\/www.aafp.org\/family-physician\/patient-care\/clinical-recommendations\/all-clinical-recommendations\/prostate-cancer.html. Accessed 3 Mar 2021."},{"key":"2099_CR85","unstructured":"The UK NSC recommendation on prostate cancer screening\/PSA testing in men over the age of 50. UK National Screening Committee, 2020. Available from:\u00a0https:\/\/legacyscreening.phe.org.uk\/prostatecancer. Accessed 3 Mar 2021."},{"key":"2099_CR86","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319:883\u201395.","journal-title":"JAMA"},{"key":"2099_CR87","first-page":"1","volume-title":"Screening for prostate cancer: external review against programme appraisal criteria for the UK National Screening Committee","author":"Costello Medical","year":"2020","unstructured":"Costello Medical. Screening for prostate cancer: external review against programme appraisal criteria for the UK National Screening Committee; 2020. p. 1\u2013365."},{"key":"2099_CR88","doi-asserted-by":"publisher","first-page":"e025470","DOI":"10.1136\/bmjopen-2018-025470","volume":"8","author":"RWM Vernooij","year":"2018","unstructured":"Vernooij RWM, Lytvyn L, Pardo-Hernandez H, Albarqouni L, Canelo-Aybar C, Campbell K, et al. Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review. BMJ Open. 2018;8:e025470.","journal-title":"BMJ Open"},{"key":"2099_CR89","volume-title":"Canadian Task Force on Preventive Health Care Procedure Manual","author":"Canadian Task Force on Preventive Health Care","year":"2014","unstructured":"Canadian Task Force on Preventive Health Care Procedure Manual.\u00a0Canadian Task Force on Preventive Health Care; 2014. Available from:\u00a0https:\/\/canadiantaskforce.ca\/methods\/. Accessed 3 Mar 2021."},{"key":"2099_CR90","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"J Higgins","year":"2011","unstructured":"Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 http:\/\/handbook.cochrane.org\/."},{"key":"2099_CR91","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"GRADE Working Group","year":"2013","unstructured":"GRADE Working Group (2013) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"2099_CR92","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"key":"2099_CR93","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic reviews. 2021;10(1):1-1.","DOI":"10.1186\/s13643-021-01626-4"},{"key":"2099_CR94","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64:395\u2013400.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR96","volume-title":"EndNote","author":"The EndNote Team","year":"2020","unstructured":"The EndNote Team (2020) EndNote."},{"key":"2099_CR97","unstructured":"Grey Matters: a practical tool for searching health-related grey literature. CADTH; 2018. Available from:\u00a0https:\/\/www.cadth.ca\/resources\/finding-evidence. Accessed 25 Apr 2019."},{"key":"2099_CR98","volume-title":"DistillerSR","author":"Evidence Partners","year":"2011","unstructured":"Evidence Partners. DistillerSR. Ottawa: Canada; 2011. https:\/\/www.evidencepartners.com\/"},{"key":"2099_CR99","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"2099_CR100","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR101","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2099_CR102","volume-title":"Holl.-Frei Cancer Med","author":"RA Smith","year":"2003","unstructured":"Smith RA, Mettlin CJ, Eyre H. Methodologic Issues in the evaluation of early detection programs. In:  Holl.-Frei Cancer Med. 6th ed; 2003.","edition":"6"},{"key":"2099_CR103","volume-title":"Cochrane Handb. Syst. Rev. Interv. Version 62 Updat","author":"J Higgins","year":"2021","unstructured":"Higgins J, Savovi\u0107 J, Page M, Elbers R, Sterne J. Chapter 8: assessing risk of bias in a randomized trial. In:  Cochrane Handb. Syst. Rev. Interv. Version 62 Updat; 2021."},{"key":"2099_CR104","volume-title":"Cochrane Collab. Cochrane Handb. Syst. Rev. Interv. 5.1.0","author":"J Higgins","year":"2011","unstructured":"Higgins J, Green S. Chapter 16: special topics in statistics. In:  Cochrane Collab. Cochrane Handb. Syst. Rev. Interv. 5.1.0; 2011."},{"key":"2099_CR105","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"2099_CR106","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jclinepi.2018.01.013","volume":"111","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Alonso-Coello P, Guyatt GH, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences\u2014risk of bias and indirectness. J Clin Epidemiol. 2019;111:94\u2013104.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR107","volume-title":"Cochrane Handb. Syst. Rev. Interv","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Sterne JA. Chapter 8: assessing risk of bias in included studies. In:  Cochrane Handb. Syst. Rev. Interv; 2011."},{"key":"2099_CR108","doi-asserted-by":"publisher","first-page":"e4705","DOI":"10.1371\/journal.pone.0004705","volume":"4","author":"G Elwyn","year":"2009","unstructured":"Elwyn G, O\u2019Connor AM, Bennett C, et al. Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). Plos One. 2009;4:e4705.","journal-title":"Plos One"},{"key":"2099_CR109","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jclinepi.2010.08.010","volume":"64","author":"R Fu","year":"2011","unstructured":"Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64:1187\u201397.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR110","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557.","journal-title":"BMJ"},{"key":"2099_CR111","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"2099_CR112","volume-title":"Cochrane Handb. Syst. Rev. Interv","author":"JJ Deeks","year":"2019","unstructured":"Deeks JJ, Higgins JP, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In:  Cochrane Handb. Syst. Rev. Interv; 2019."},{"key":"2099_CR113","volume-title":"Methods for meta-analysis in medical research","author":"AJ Sutton","year":"2000","unstructured":"Sutton AJ. Methods for meta-analysis in medical research: Wiley; 2000."},{"key":"2099_CR114","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.","journal-title":"BMJ"},{"key":"2099_CR115","unstructured":"Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A product from the ESRC methods programme Version. 2006;1(1):b92."},{"key":"2099_CR116","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66:158\u201372.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR117","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles\u2014continuous outcomes. J Clin Epidemiol. 2013;66:173\u201383.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR118","volume-title":"Cochrane Handb. Syst. Rev. Interv. Version 62 Updat","author":"JJ Deeks","year":"2021","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In:  Cochrane Handb. Syst. Rev. Interv. Version 62 Updat; 2021."},{"key":"2099_CR119","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351\u201375.","journal-title":"Stat Med"},{"key":"2099_CR120","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","volume":"323","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101\u20135.","journal-title":"BMJ"},{"key":"2099_CR121","doi-asserted-by":"publisher","first-page":"e15987","DOI":"10.1097\/MD.0000000000015987","volume":"98","author":"L Shi","year":"2019","unstructured":"Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019;98:e15987.","journal-title":"Medicine (Baltimore)"},{"key":"2099_CR122","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64:1311\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2018.05.011","volume":"111","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Coello PA, Guyatt GH, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences\u2014inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83\u201393.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR124","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Mustafa RA, Sch\u00fcnemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22:85\u20137.","journal-title":"Evid Based Med"},{"key":"2099_CR125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","volume":"87","author":"M Hultcrantz","year":"2017","unstructured":"Hultcrantz M, Rind D, Akl EA, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4\u201313.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR126","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","volume":"137","author":"L Zeng","year":"2021","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol. 2021;137:163\u201375.","journal-title":"J Clin Epidemiol"},{"key":"2099_CR127","doi-asserted-by":"crossref","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hultcrantz M, Kuijpers T. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126-35.","DOI":"10.1016\/j.jclinepi.2019.10.014"},{"key":"2099_CR128","volume-title":"Reporting the effects of an intervention in EPOC reviews. EPOC Resources for review authors","author":"Cochrane Effective Practice and Organisation of Care (EPOC)","year":"2018","unstructured":"Cochrane Effective Practice and Organisation of Care (EPOC) (2018) Reporting the effects of an intervention in EPOC reviews. EPOC Resources for review authors."},{"key":"2099_CR129","first-page":"353","volume-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","author":"A-C Pablo","year":"2016","unstructured":"Pablo A-C, Sch\u00fcnemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction; 2016. p. 353\u2013i2016."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02099-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-02099-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02099-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T05:06:00Z","timestamp":1667106360000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-02099-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-02099-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish was obtained from the stakeholders who provided feedback on the protocol. A copy of the written consent is available for review by the Editors-in-Chief of this journal. The stakeholder feedback has been anonymized and included as Additional file .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Moher was previously Co-Editor-in-Chief with <i>Systematic Reviews<\/i>. Philipp Dahm serves as the Coordinating Editor of Cochrane Urology. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}